Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs
The RADx® Tech program is part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID.
The MakeMyTestCount.org website is an easy way to anonymously report test results for any brand of at-home COVID-19 test. This helps public health departments to assess needs and provide resources. Report your test results here.
COVID-19 Research across NIBIB
Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.
Videos
View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.
Program Contacts
RADx® Tech/ATP programmatic or technical inquiries: info.radx@poctrn.org
All other RADx® Tech/ATP Applicants: RADxNIBIB@mail.nih.gov
SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov
All others: COVID19NIBIB@nih.gov
Related Resources
Learn about clinical trials for treatments and vaccines at HHS Combat COVID
NIH COVID-19 Information for Applicants/Grantees
Media Inquiries: nibibpress@mail.nih.gov or 301-496-3500
About COVID-19
Research information from NIH | Español
Related News
NIBIB bioengineer Kaitlyn Sadtler has flourished as a leader of many impactful, interdisciplinary studies. For her role in shaping the future of medical research, TIME magazine has named Kaitlyn Sadtler to the TIME100 Next 2024 List.
NIBIB-funded researchers are working to bring in vivo gene editing to the fore. Through rational engineering of lipid nanoparticles, this collaborative team developed a way to effectively target specific organs in the body to precisely deliver therapeutic cargo, including gene-editing molecules. Their research demonstrated that a one-time treatment with their nanoparticles resulted in durable gene editing in mouse lungs for nearly two years. Further, their technique showed promise in correcting a mutation present in a currently untreatable form of cystic fibrosis in several models of the disease.
Due to its high accuracy, lab-based PCR testing is the gold standard for infectious disease diagnostics. Yet PCR's availability is limited, especially in low-resource settings. New research suggests a new kind of test could be more streamlined without sacrificing performance.
Researchers have established an RNA-based method that drives cells in the body to produce therapeutic proteins and secrete them into the bloodstream. The approach could extend the lifespan of drugs in the body, reducing the burden on patients.
To date, nine medical device developers participating in the RADx® Tech Independent Test Assessment Program have received emergency use authorization for at-home and point-of care test products that simultaneously detect COVID-19 and flu A/B.